HCV Populations
INHSU 2017: People Who Use Drugs Should Be Prioritized for Hepatitis C Treatment
- Details
- Category: People Who Inject Drugs
- Published on Thursday, 21 September 2017 00:00
- Written by INHSU
People who use drugs should be given high priority for antiviral treatment as a way to eliminate hepatitis C as a public health concern, according to a statement issued at the 6th International Symposium on Hepatitis Care in Substance Users, held earlier this month in Jersey City.
PAS 2017: Sofosbuvir Plus Ribavirin Cures Teens with Genotype 2 or 3 Hepatitis C
- Details
- Category: Children & Adolescents
- Published on Tuesday, 16 May 2017 00:00
- Written by Liz Highleyman
A 2-drug regimen of sofosbuvir (Sovaldi) and ribavirin taken for 12 weeks led to sustained virological response in all treated adolescents with hepatitis C virus (HCV) genotype 2, while a 24-week course cured all but one teen with harder-to-treat genotype 3, according to a presentation at the 2017 Pediatric Academic Societies Meeting last week in San Francisco.
BHIVA 2017: London Data Shows Hepatitis C Is Transmitted During Anal Sex Without Condoms
- Details
- Category: Gay & Bisexual Men/MSM
- Published on Thursday, 13 April 2017 00:00
- Written by Roger Pebody
Around 1 in 5 HIV-positive gay men who recently acquired hepatitis C virus (HCV) report anal sex without a condom as the only behavior that could explain their infection. At the same time, a third of people acquiring HCV were gay men who did not have HIV, clinicians from the Mortimer Market Centre in London reported at the British HIV Association (BHIVA) conference last week in Liverpool. The data suggest that prevention messages around sexually transmitted hepatitis C need to change.
CROI 2017: Hepatitis C Treatment Can Be Provided Successfully at Syringe Exchange Sites
- Details
- Category: People Who Inject Drugs
- Published on Thursday, 13 April 2017 00:00
- Written by Liz Highleyman
Administering direct-acting antiviral therapy for people who inject drugs at a syringe exchange site led to high sustained response rates in a pilot study in New York City, researchers reported at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Expanding treatment for this population could reduce hepatitis C virus (HCV) transmission and ultimately help eliminate hepatitis C as a public health threat.
Coverage of 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016)
- Details
- Category: People Who Inject Drugs
- Published on Friday, 30 September 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016), September 7-9 in Oslo, Norway.
Highlights include hepatitis C treatment for people who inject drugs and people in prison, extra-hepatic manifestations of hepatitis C, and development of an HCV vaccine.
9/3016
More Articles...
- Interferon-Free Hepatitis C Treatment Safe and Effective for People Who Inject Drugs
- EASL 2016: HCV Therapy Improves Quality of Life for People Who Inject Drugs, Reinfection Risk Remains
- Coverage of 4th International Symposium on Hepatitis Care in Substance Users (INHSU 2015)
- INHSU 2015: HCV Treatment Works Well for People Who Inject Drugs, but Barriers to Access Remain
Web Design and Development by